Safety and Efficacy of Cariprazine in Schizophrenia
Public ClinicalTrials.gov record NCT01104779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Study identification
- NCT ID
- NCT01104779
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Forest Laboratories
- Industry
- Enrollment
- 446 participants
Conditions and interventions
Conditions
Interventions
- Cariprazine Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 26, 2010
- Primary completion
- Dec 14, 2011
- Completion
- Dec 14, 2011
- Last update posted
- Nov 13, 2018
2010 – 2011
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Forest Investigative Site 48 | Costa Mesa | California | 92626 | — |
| Forest Investigative Site 50 | Long Beach | California | 90813 | — |
| Forest Investigative Site 42 | Paramount | California | 90723 | — |
| Forest Investigative Site 054 | San Diego | California | 92102 | — |
| Forest Investigative Site 41 | Kissimmee | Florida | 34741 | — |
| Forest Investigative Site 055 | Atlanta | Georgia | 30308 | — |
| Forest Investigative Site 44 | Rockville | Maryland | 20850 | — |
| Forest Investigative Site 45 | St Louis | Missouri | 63118 | — |
| Forest Investigative Site 52 | Las Vegas | Nevada | 89102 | — |
| Forest Investigative Site 40 | Cedarhurst | New York | 11516 | — |
| Forest Investigative Site 46 | Cincinnati | Ohio | 45219 | — |
| Forest Investigative Site 47 | Philadelphia | Pennsylvania | 19139 | — |
| Forest Investigative 49 | Memphis | Tennessee | 38119 | — |
| Forest Investigative Site 51 | Houston | Texas | 77021 | — |
| Forest Investigative Site 43 | Irving | Texas | 75062 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01104779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 13, 2018 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01104779 live on ClinicalTrials.gov.